Veracyte Decipher Test Shows Predictive Evidence in Prostate Cancer Study

Veracyte said a retrospective Phase III STAMPEDE analysis provides Level 1B evidence that its Decipher Prostate test can identify very high-risk, nonmetastatic patients who may benefit from adding abiraterone to ADT.